Latest Industry News & Trends

Q2-2025 Ophthalmic Revenue Roundup for Roche, Bausch + Lomb, Apellis, Glaukos, and Astellas

Swiss company Roche reported July 24 that Vabysmo sales for Q2-2025 were CHF 1.05 billion ($1.3 billion, converted June 30, 2025), a 19 percent increase over CHF 947 million in Q2-2024. Roche said ...

CMS Proposes Lower Physician Payments in 2026, Higher HOPD and ASC Fees

US ophthalmologists are gaining some clarity on what their reimbursement for treating Medicare patients may look like in 2026. Documents published by the Centers for Medicare and Medicaid Services ...

Onconetix to Merge with Glaucoma Drop Maker Ocuvex

Onconetix, of Cincinnati, Ohio, announced July 16 a definitive merger agreement with Ocuvex, maker of Omlonti (omidenepag isopropyl 0.002%) drops for glaucoma. The combined company will carry the O...

Alcon Aims to Extend Ultrasonic Phaco Dominance with Launch of Unity CS

Alcon launched the Unity VCS and CS machines in April at the annual meeting of the American Society of Cataract and Refractive Surgery, looking to continue its global dominance in the cataract mach...

J&J Vision Launches Tecnis Odyssey PC-IOL in Europe, Middle East, and Canada

Johnson & Johnson Vision announced June 17 that it had rolled out the Tecnis Odyssey presbyopia-correcting intraocular lens (PC-IOL) in Europe, the Middle East, and Canada. The Odyssey had previous...

Select US FDA Approvals and Clearances in June 2025

The US FDA’s ophthalmic device division granted clearance to three devices using the 510(k) pathway in June 2025, according to the agency’s database. Zeiss received clearance for its Micor 700 syst...

ForSight Leads Latest Ophthalmic Fundraising with $125 Million in Series B

Israel’s ForSight Robotics led recent ophthalmic fundraising efforts with $125 million in Series B funding as it prepares its robotic cataract surgery system for human trials. Financing announced i...

2025-2026 Ophthalmic Meetings Calendar

Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.

Weekly Surgeon Poll, July 2025

July 2025 Ophthalmic News Briefs

Hoya Vision Care announced June 2 that it had acquired Centennial Optical, a Canadian distributor of ophthalmic frames, eyeglass lenses, sunglasses, lab supplies, and optical accessories. Financial...

J&J Vision Generates Q2-2025 Surgical Revenue of $403 Million

J&J Vision’s Q2-2025 global surgical revenue totaled $403 million, a 9.9 percent increase (+8.9 percent cc) over $367 million in Q2-2024, parent Johnson & Johnson, of New Brunswick, New Jersey, rep...

Israel’s PainReform Enters Ophthalmology with Investment in LayerBio

Israel’s PainReform announced July 10 that it had signed a strategic agreement with LayerBio, which is developing OcuRing-K, a sustained-release intraocular implant designed to deliver anti-inflamm...

Ocumetics Begins First-in-Human Study of its Accommodating IOL

Ocumetics Technology, of Calgary, Canada, announced June 24 that it was set to begin a first-in-human clinical study of its accommodating intraocular lens (IOL). The company said all the lenses for...

RxSight Lowers 2025 Guidance Due to Q2-2025 Preliminary Results

RxSight reported July 8 that it was lowering its 2025 revenue guidance to $120 million to $130 million, down from the range of $185.0 million to $197.0 million provided on Feb. 25, 2025. The Aliso ...

Alcon Unity VCS Dual-Function System Gains Approval in Canada

Alcon announced July 8 that its dual-function Unity Vitreoretinal Cataract System (VCS) had gained market approval from Health Canada. Commercial launch in Canada is expected in early 2026, the com...

CMS to Increase Audits of Medicare Advantage Billing to Prevent Upcoding

Private insurers that take part in the US Medicare Advantage program will see enhanced and accelerated audits of their billing practices under an aggressive new plan, the Centers for Medicare and M...

Donor Gives $40M to Ophthalmology Department at CU Anschutz in Colorado 

An anonymous donor has given a $40 million gift for eye research to the Department of Ophthalmology at the University of Colorado (CU) AnschutzMedical Campus in Aurora, Colorado, the school announc...

Health Insurers Pledge to Reform Prior Authorization by 2026

Major insurers of nearly 50 US health plans published a pledge on June 24 to simplify and reduce prior authorization of medical treatments, cutting the volume of treatments subject to such oversigh...

Alcon Unity Cataract and Dual-Function Systems Gain Approval in Brazil

Alcon announced June 12 that its dual-function Unity Vitreoretinal Cataract System (VCS) and stand-alone Unity Cataract System (CS) had gained market approval from the Brazilian Health Regulatory A...

VivaVision, US FDA Agree on Accelerated Path for Post-op Inflammation Candidate

VivaVision, of Wenzhou, China, announced June 9 that the US FDA had agreed on an accelerated regulatory pathway for the company’s VVN461LD, a potent JAK1/TYK2 inhibitor targeting inflammation follo...

EssilorLuxottica to Acquire European Ophthalmology Clinic Chain Optegra

Eyewear conglomerate Essilor-Luxottica announced May 30 that it would acquire the Optegra chain of ophthalmology clinics from the private equity firm MidEuropa. Financial details were not disclosed...

Harrow Acquires US Rights to Formosa’s Clobetasol, Now Branded Byqlovi

Harrow announced June 9 that it had acquired the US commercial rights to Formosa Pharmaceuticals’ clobetasol propionate 0.05% eye drops for postsurgical inflammation and pain. According to a filing...

Weekly Corporate and Surgeon Polls, June 2025

J&J Vision Launches Tecnis Odyssey PC-IOL in Europe, Middle East, and Canada

Johnson & Johnson Vision announced June 17 that it had rolled out the Tecnis Odyssey presbyopia-correcting intraocular lens (PC-IOL) in Europe, the Middle East, and Canada. The company, based in Ja...

Harrow Acquires US Rights to Formosa’s Clobetasol, Now Branded Byqlovi

Harrow announced June 9 that it had acquired the US commercial rights to Formosa Pharmaceuticals’ clobetasol propionate 0.05% eye drops for postsurgical inflammation and pain. According to a filing...

EssilorLuxottica to Acquire European Ophthalmology Clinic Chain Optegra

Eyewear conglomerate EssilorLuxottica announced May 30 that it would acquire the Optegra chain of ophthalmology clinics from the private equity firm MidEuropa. Financial details were not disclosed....

Formosa Licenses Clobetasol Drops to Adalvo for European, Brazilian Markets

Taiwan-based Formosa Pharmaceuticals announced May 28 that it had agreed to license to Malta’s Adalvo Limited exclusive rights to market clobetasol propionate 0.05% eye drops for postsurgical infla...

Atia Vision Gains IDE Approval to Begin US Trial of Modular Accommodating IOL

Atia Vision announced May 20 that the FDA had approved its investigational device exemption (IDE) application to begin a US feasibility study of its OmniVu modular accommodating lens system for cat...

Q1-2025 Ophthalmic Revenue Roundup for Bausch + Lomb and Carl Zeiss Meditec

Bausch + Lomb reported April 30 that its Q1-2025 revenue was $1.14 billion, a 3 percent increase (+5 percent cc) over $1.10 billion in Q1-2024. Vision Care segment revenue in Q1-2025 was $656 milli...

X-Rounds Session Provides Rapid-fire Insights on What’s Hot, What’s Not

A session titled “X-Rounds: Cataract Surgery to the Max” focused on the latest advancements and innovations in refractive cataract surgery. The session was packed, drawing the largest audience of t...

ASCRS Panel Examines Digital Visualization’s Ergonomics and Efficiency

Panelists at an ASCRS symposium on digital visualization in surgery embraced advancements, while addressing longstanding concerns about ergonomics and efficiency. The panel members emphasized minim...

Bausch + Lomb Ends Recall of enVista IOLs After Tracking Source of Contamination

Bausch + Lomb announced April 24 that it was ending its voluntary recall of enVista intraocular lenses (IOLs) after it tracked the source of contamination to a raw material used in certain lots tha...

Alcon Emphasizes Efficiency of Unity VCS and CS Systems at ASCRS Launch

Surgeons attending the 2025 ASCRS meeting in Los Angeles dropped by Alcon’s booth for multiple presentations of the new Unity dual-function and cataract machines, rather than gathering in big numbe...

Zeiss’ Veracity Surgery Planner Driving Innovation in Cataract Care

Carl Zeiss Meditec celebrated over 2 million cataract cases planned with Veracity during the ASCRS meeting in Los Angeles. A talk with Kerry Solomon, MD, at the Zeiss booth highlighted the surgical...

Alcon Launches PanOptix Pro Trifocal Lens at 2025 ASCRS Meeting

Alcon formally launched the Clareon PanOptix Pro trifocal IOL in various venues at the 2025 ASCRS meeting. Events included booth presentations by Robert Melendez, MD, Morgan Micheletti, MD, Jennife...

Rayner’s Sophi, Zeiss’ Micor 700 Showcased at the 2025 ASCRS Meeting

Rayner and Carl Zeiss Meditec showcased cataract surgical systems at the 2025 ASCRS meeting. UK-based Rayner featured the Sophi ultrasonic phaco machine at its booth. The Sophi is notable for its w...

Maximilian Foerst to Lead Carl Zeiss Meditec; Markus Weber, PhD, Steps Down

Carl Zeiss Meditec announced May 7 that Markus Weber, PhD, the company’s president and CEO, will step down of his own accord, effective May 31. Replacing Weber will be Maximilian Foerst, currently ...

Ballooning NHS Cataract Surgery Costs at Private Clinics Raise Red Flags

Fraud investigators in England’s National Health Service (NHS) are looking at the billing practices of private clinics delivering NHS cataract surgery after procedure volume and costs have balloone...

Laws in Montana, West Virginia Expand ODs’ Scope to Include Laser

Montana and West Virginia became the 13th and 14th US states, respectively, to pass laws expanding optometrists’ scope of practice to include in-office laser procedures. West Virginia’s measure spe...

Weekly Surgeon Poll, May 2025

May 2025 Ophthalmic News Briefs

London’s Okyo Pharma announced April 30 that it would accelerate development of topical urcosimod, formerly OK-101, in neuropathic corneal pain, following early closure of its Phase II trial. The t...

Bausch + Lomb Receives CE Marking for Preloaded LuxLife Trifocal IOL

Bausch + Lomb announced May 7 that the LuxLife trifocal intraocular lens (IOL) had received CE marking in Europe. The company said the nondiffractive LuxLife has an uninterrupted, continuous refrac...

Q1-2025 Ophthalmic Revenue Roundup for Alcon, Immunocore, Harrow, Sight Sciences, ANI, Iridex, and Xbrane

Alcon reported May 13 that its Q1-2025 net sales were $2.45 billion, on par with $2.44 billion in Q1-2024 and up 3 percent on a constant currency basis. Surgical net sales totaled $1.33 billion (do...

Maximilian Foerst to Lead Carl Zeiss Meditec, as Markus Weber, PhD, Steps Down

Carl Zeiss Meditec announced May 7 that Markus Weber, PhD, the company’s president and CEO, will step down of his own accord, effective May 31. Replacing Weber will be Maximilian Foerst, currently ...

Q1-2025 Ophthalmic Revenue Roundup for Amgen, Hoya, Apellis, Tarsus, STAAR, RxSight, and Ocular Therapeutix

​ Amgen, of Thousand Oaks, California, reported May 1 that its Q1-2025 revenue from Tepezza was $381 million, a 10 percent decrease from $424 million in Q1-2024. The total consisted of $365 million...

Formosa Licenses Clobetasol Propionate Drops to Chile’s Saval for Latin America

Taiwan-based Formosa Pharmaceuticals announced April 25 that it had agreed to license to Chile’s Laboratorios Saval exclusive rights to market clobetasol propionate 0.05% eye drops for postsurgical...

Bausch + Lomb Ends Recall of enVista IOLs After Tracking Source of Contamination

Bausch + Lomb announced April 24 that it was ending its voluntary recall of enVista intraocular lenses (IOLs) after it tracked the source of contamination to a raw material used in certain lots tha...

Alcon Rolls Out Unity VCS and CS Systems at ASCRS Meeting

Alcon announced April 25 the launch of its dual-function Unity Vitreoretinal Cataract System (VCS) and stand-alone Unity Cataract System (CS) in four markets, including the US. The announcement cam...

Ballooning NHS Cataract Surgery Costs at Private Clinics Raise Red Flags

Fraud investigators in England’sNational Health Service (NHS) are looking at the billing practices of private clinics delivering NHS cataract surgery after procedure volume and costs have ballooned...

New Mexico Governor Vetoes Bill to Allow ODs to Perform SLT, YAG Capsulotomy

New Mexico Gov. Michelle Lujan Grisham on April 11 vetoed House Bill 36, which would have expanded the scope of practice for optometrists in the state, allowing them to perform selective laser trab...

Better IOLs, Push from Surgeons Will Drive Healthy Premium Growth

Cataract surgeons’ focus on premium IOLs will increase over the next five years due to improved technology and continued declines in reimbursement for monofocal cataract surgery. Premium IOLs, incl...

Alcon Agrees to Buy Lensar in Deal Worth up to $430 Million

Alcon announced March 24 that it had entered into a definitive agreement to acquire Lensar, including its Ally femtosecond laser cataract system, its Streamline software, and the Lensar legacy lase...

Alcon Introduces Clareon PanOptix Pro IOL

Alcon on April 2 introduced its Clareon PanOptix Pro trifocal IOL, a next-generation version of its groundbreaking PanOptix model. The company said the lens had been made available to select US pra...

Bausch + Lomb Recalls Certain enVista IOLs Amid Reports of TASS Cases

Bausch + Lomb announced March 27 that it was voluntarily recalling certain intraocular lenses (IOLs) on its enVista platform. A letter to customers from Bausch + Lomb Chairman and CEO Brent Saunder...

April 2025 Ophthalmic News Briefs

Carl Zeiss Meditec announced March 21 the availability in Canada of the Visulas Combi, a green and YAG ophthalmic laser workstation combining photodisruption, photocoagulation, and slit lamp techno...

J&J Vision Reports Q1-2025 Surgical Revenue of $361 Million

J&J Vision’s Q1-2025 global surgical revenue totaled $361 million, a 3.7 percent increase (+6.2 percent cc) over $348 million in Q1-2024, parent Johnson & Johnson, of New Brunswick, New Jersey, rep...

US FDA Issues Update on Bausch + Lomb enVista IOL Recall

The US FDA issued an update April 7 with more details on Bausch + Lomb’s voluntary recall of certain intraocular lenses (IOLs) on its enVista platform. The update listed the affected lenses: —enVis...

Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex

Onconetix, of Cincinnati, Ohio, announced April 8 that it had signed a non-binding letter of intent contemplating a potential business combination with Ocuvex, maker of Omlonti (omidenepag isopropy...

Alcon Introduces Clareon PanOptix Pro Trifocal IOL

Alcon on April 2 introduced its Clareon PanOptix Pro trifocal IOL, a next-generation version of its groundbreaking PanOptix model. The company said the PanOptix Pro had been made available to selec...

Rayner Doubles IOL Manufacturing Capacity with Expansion of Facility

Rayner announced April 2 that it had completed an expansion of its production facility in Worthing, UK, doubling the number of intraocular lenses (IOLs) it can manufacture annually to 4 million. Th...

Bausch + Lomb Recalls Certain enVista IOLs Amid Reports of TASS Cases

Bausch + Lomb announced March 27 that it was voluntarily recalling certain intraocular lenses (IOLs) on its enVista platform. A letter to customers from Bausch + Lomb Chairman and CEO Brent Saunder...

Alcon Agrees to Buy Lensar in Deal Worth up to $430 Million

Alcon announced March 24 that it had entered into a definitive agreement to acquire Lensar, including its Ally femtosecond laser cataract system, its Streamline software, and the Lensar legacy lase...

Alcon Announces CE Mark Approval, European Launch of Clareon Vivity IOL

Alcon reported March 25 that the Clareon Vivity extended depth of focus (EDOF) intraocular lens (IOL) had received CE marking, along with the toric model, and will begin a commercial rollout in Eur...

BVI Leads Latest Ophthalmic Fundraising with $1 Billion in Strategic Capital

BVI Medical led recent ophthalmic fundraising efforts with $1 billion in strategic capital, raised from owner TPG and new investors, to continue expanding globally. Financing announced in the past ...

2024 Ophthalmic Revenue Roundup for Apellis, Immunocore, Sight Sciences, Ocular Therapeutix, Lensar, and ANI

Apellis Pharmaceuticals, of Waltham, Massachusetts, reported Feb. 28 that its 2024 net product revenue for Syfovre was $611.8 million, a 122.3 percent increase over $275.2 million in 2023. The comp...

2024 Ophthalmic Revenue Roundup for Alcon, Glaukos, Tarsus, and RxSight

Alcon reported Feb. 25 that its full year 2024 net sales totaled $9.8 billion, a 5 percent increase (+6 percent cc) over $9.4 billion in 2023. Q4-2024 sales were $2.5 billion, a 6 percent increase ...

Select US FDA Approvals and Clearances in January 2025

There were no US FDA clearances through the ophthalmic device division using the 510(k) pathway in January 2025, according to the agency’s database. This is a departure from previous months, when i...

Retrospective Study Finds Link Between IVT Injections, Cataract Surgery Complications

Researchers from the Byers Eye Institute at Stanford Health Care in Palo Alto, California, have found that cataract patients with prior intravitreal (IVT) injections face more complications after c...

Weekly Surgeon Polls, February 2025

2024 and Quarterly Ophthalmic Revenue Roundup for Regeneron, Carl Zeiss Meditec, Hoya, and STAAR

Regeneron, of Tarrytown, New York, reported Feb. 4 that its 2024 US revenue for Eylea 2 mg (aflibercept 2 mg) and Eylea HD (aflibercept 8 mg) totaled nearly $5.97 billion, a 1 percent increase over...

Retrospective Study Finds Link Between IVT Injections, Cataract Surgery Complications

Researchers from the Byers Eye Institute at Stanford Health Care in Palo Alto, California, have found that cataractpatients with prior intravitreal (IVT) injections face more complications after ca...

Health Canada Approves Rayner’s RayOne EMV Toric IOL

UK-based Rayner announced Jan. 21 that Health Canada had approved the toric version of its RayOne EMV enhanced monofocal intraocular lens (IOL). The non-toric version of the lens was approved in Ca...

2024 in Review: Zeiss' Rollout of Micor 700 Shakes Up Cataract Equipment Market in US

German company Carl Zeiss Meditec’s US launch of its Micor 700 handpiece for cataract surgery in 2024 represented a significant step forward in innovation. The Micor offers an entirely new way to s...

Bausch Kicks off 2025 With Series of Research Deals, Plus an IOL Launch

Bausch + Lomb has recently announced a series of acquisitions and collaborations that it says will bolster its expanding pipeline and help address unmet needs in ophthalmology. It also launched an ...

2024 in Review: Corporate and Surgeon Rankings of Top 10 Stories

Market Scope asked industry participants and surgeons to select the top story for 2024. Below are their choices. Zeiss’ Rollout of Micor 700 Shakes Up Cataract Equipment Market in US MAC Turmoil Sh...

2024 in Review: Newest PC-IOLs Helped Drive Worldwide Growth in 2024

At least a dozen trifocal and EDOF IOLs were launched in key markets over the past 18 months, spurring worldwide growth and giving presbyopia-correcting lenses a small uptick in their market share ...

Weekly Surgeon Poll, January 2025

Johns Hopkins Scientists Develop Clear OVD That Glows Under Blue Light

Scientists at Johns Hopkins University have developed a clear ophthalmic viscosurgical device (OVD) that turns fluorescent green under blue light, allowing surgeons to verify complete removal of th...

Ophthalmic Revenue Roundup for Carl Zeiss Meditec, Amgen, Biogen

Carl Zeiss Meditec reported Dec. 11 that ophthalmology revenue for its full fiscal year 2023/2024, which ended Sept. 30, was €1.59 billion (US $1.7 billion, converted Dec. 11, 2024), an increase of...

Johns Hopkins Scientists Develop Clear OVD That Glows Under Blue Light

Scientists at Johns Hopkins University have developed a clear ophthalmic viscosurgical device (OVD) that turns fluorescent green under blue light, allowing surgeons to verify complete removal of th...

Nidek Launches NP-T Preloaded Toric IOL Injector Globally

Japanese ophthalmic company Nidek announced Dec. 2 that it had launched the NP-T preloaded toric intraocular lens (IOL) injection system globally. Previously, the injector had been available only i...

Clinical Trial Updates for Ophthalmic Candidates, December 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

Lineage Leads Latest Ophthalmic Fundraising with $66 Million Offering

Lineage Cell Therapeutics led recent ophthalmic fundraising efforts with a registered direct offering worth up to $66 million to advance its RPE cell therapy candidate. Financing announced in the p...

CMS Cuts Ophthalmologists’ Procedure Fees, While Raising ASC, HOPD Facility Fees

The Centers for Medicare and Medicaid Services (CMS) published on Nov. 1 the final schedule of Medicare reimbursement fees for physicians in 2025. It also released its facility fee payments for ASC...

Medvisis to Market Clobetasol Drops in Switzerland, Liechtenstein, Under License with Formosa

Swiss company Medvisis has obtained exclusive rights to market clobetasol propionate eye drops in Switzerland and Liechtenstein for inflammation and pain following ocular surgery under a license ag...

Harrow Lowers Price of Drugs through GoodRx Partnership, Price Cuts

Harrow, of Nashville, Tennessee reported Nov. 13 that it had entered into a partnership with GoodRx to provide patients for whom insurance is not a viable option a cash-pay alternative. Harrow prod...

CMS Cuts Ophthalmologists’ Procedure Fees, While Raising ASC, HOPD Facility Fees

The Centers for Medicare and Medicaid Services (CMS) published on Nov. 1 the final schedule of Medicare reimbursement fees for physicians in 2025. It also released its facility fee payments for ASC...

Harrow’s ImprimisRx Unit Gets $34.9 Million Trademark Infringement Verdict

Harrow’s ImprimisRx subsidiary received a $34.9 million verdict on Nov. 20, 2024, in a trademark infringement lawsuit against OSRX Pharmaceuticals, of Missoula, Montana. OSRX is an affiliate of Ocu...

Q3-2024 Ophthalmic Revenue Roundup for Immunocore, Harrow, Tarsus, Lumibird, and Ocular Therapeutix

UK-headquartered Immunocore reported Nov. 6 that its Q3-2024 net revenue from Kimmtrak (tebentafusp) was $80.2 million, a 28 percent increase over $62.6 million in Q3-2023. Regionally, Kimmtrak net...

Q3-2024 Ophthalmic Revenue Roundup for Alcon, Hoya, RxSight, Sight Sciences, and Iridex

Alcon reported Nov. 12 that its Q3-2024 net sales totaled $2.4 billion, a 6 percent increase over $2.3 billion in Q3-2023. Surgical net sales for implantables, consumables, and equipment/other were...

Zeiss Bolsters Launch of Micor 700 at AAO Meeting With US Surgeons Discussing Adoption

Carl Zeiss Meditec featured its Micor 700 at the 2024 meeting of the American Academy of Ophthalmology in Chicago, Illinois, with presentations that included booth talks by select US surgeons who h...

Office-Based Surgery Garners Enthusiasm at 2024 AAO Meeting

Several sessions at the 2024 American Academy of Ophthalmology meeting highlighted the trend of office-based surgery (OBS) and the option of oral sedation among practitioners. The consensus among t...

New Trifocal IOLs Expected to Help the US Resume PC-IOL Growth

Bausch + Lomb’s enVista Envy and J&J Vision’s Odyssey are two new trifocal IOLs that were shown at the 2024 AAO meeting in Chicago. They are expected to help reverse the decline in trifocal IOL sal...

Private Practices Key to US Premium Cataract Surgery Market Dominance

The US represents only 5 percent of the global population in 2024, but it accounts for nearly 36 percent of the world’s premium cataract surgery (PCS) market revenue. The US has the latest premium ...

Clinical Trial Updates for Ophthalmic Candidates, November 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

November 2024 Ophthalmic News Briefs

Heidelberg Engineering announced Oct. 14 that the US FDA had granted 510(k) clearance to its Flex Module for the Spectralis diagnostic imaging platform. The Flex Module mounts the Spectralis to a m...

Q3-2024 Ophthalmic Revenue Roundup for AbbVie, Apellis, Glaukos, STAAR, and Lensar

AbbVie, of North Chicago, Illinois, reported Oct. 30 that its Q3-2024 eye care net revenue was $525 million, a 13.5 percent decline (-11.2 percent cc) from $605 million in Q3-2023. Restasis revenue...

DÁVI Licenses Clobetasol Propionate Post-op Drops from Formosa for Portugal

Taiwan-based Formosa Pharmaceuticals announced Oct. 31 that it had entered into an exclusive licensing agreement with DÁVI Farmacêutica, of Portugal, for the rights there to market clobetasol propi...

Bausch + Lomb Gains US FDA Approval of enVista Envy Trifocal IOL

Bausch + Lomb reported Oct. 14 that the US FDA had approved itsenVista Envy trifocal intraocular lens. The lens is available on a limited basis in the US and will be launched more broadly in 2025. ...

First ASCRS Business Summit Breaks Down Premium Surgery’s Role in Practice Success

The first-ever ASCRS Business of Refractive Cataract Surgery (BRiCS) Summit was a two-day course designed to equip practices with the knowledge, resources, and confidence to boost their adoption of...

Cure Blindness Project Expands Sight-Saving Care to Six New Countries

Cure Blindness Project is expanding to six new countries—Burundi, Democratic Republic of the Congo, Liberia, Pakistan, Paraguay, and Zambia, the charity reported Oct. 10. Paraguay marksthe charity’...

Lensar Marks 1 Million Procedures Using its Femtosecond Cataract Lasers

Lensar reported Oct. 8 that surgeons had performed more than 1 million procedures using its Lensar femtosecond cataract systems. The Orlando, Florida, company introduced its original Lensar Laser S...

Zeiss Begins Broad US Rollout of Micor 700 for Phaco-less Cataract Surgery

Zeiss Medical Technology reported Sept. 26 that it had begun broad US distribution of the Micor 700, the first hand-held device to extract a crystalline lens in cataract surgery without the need fo...

Eyenovia Launches Clobetasol Drops for Postoperative Pain and Inflammation

Eyenovia announced Sept. 26 the US launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05%, known as Clobetasol, for postoperative inflammation and pain following oc...

NEI Researchers Identify Protein That Clears Cataracts in Animals

Researchers at the National Eye Institute (NEI), working with counterparts in China, have discovered a reversible cataract response in hibernating squirrels that may point toward a nonsurgical trea...

Rayner Begins US Study of RayOne Galaxy Trifocal Spiral IOL

UK-based Rayner reported Oct. 1 that the first RayOne Galaxy lenses had been implanted in the US as part of an FDA investigational device exemption (IDE) study. Rayner describes the Galaxy, a trifo...

Eyenovia Launches Clobetasol Drops for Postoperative Pain, Inflammation

Eyenovia announced Sept. 26 the US launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05%, known as Clobetasol, for postoperative inflammation and pain following oc...

NEI Researchers Identify Protein That Clears Cataracts in Animals

Researchers at the National Eye Institute (NEI), working with counterparts in China, have discovered a reversible cataract response in hibernating squirrels that may point toward a nonsurgical trea...

Zeiss Announces Broad US Rollout of Micor 700 for Phaco-less Cataract Surgery

Carl Zeiss Meditec reported Sept. 26 that it had begun broad US distribution of the Micor 700, the first hand-held device to extract a crystalline lens in cataract surgery without the need for ultr...

Ophthalmologists Report 0.5 Percent Increase in Q2-2024 Procedure Volume

US ophthalmologists reported that ophthalmic procedures increased 0.5 percent in Q2-2024 compared with the same quarter in 2023, according to Market Scope’s latest survey. Year-over-year performanc...

ONL Leads Latest Ophthalmic Fundraising with $65M Series D Round

ONL Therapeutics led recent ophthalmic fundraising efforts with a $65 million Series D round to continue advancing its small-molecule Fas inhibitor for retinal disease. Financing announced in the p...

Oculis Shuts Down Phase III Trial of OCS-01 Due to Third-Party Administrative Error

Swiss company Oculis reported Aug. 27 in its Q2-2024 financial statement that it was shutting down the Phase III OPTIMIZE-2 trial of its OCS-01 eye drop candidate for postsurgical inflammation and ...

Visiox to Merge with Ocuvex to Advance Two Ophthalmic Drug Candidates

Visiox Pharmaceuticals announced Aug. 19 that it had agreed to merge with Ocuvex Therapeutics, a privately held company in New Hyde Park, New York. A Visiox news release said Ocuvex has a pipeline ...

Precision Lens and Estate of Paul Ehlen to Pay US $12M over Kickbacks

Minnesota-based ophthalmic distributor Precision Lens and the estate of co-founder Paul Ehlen have agreed to pay the US government $12 million to resolve a case involving kickback payments in vario...

Weekly Surgeon Poll, September 2024

Livionex’ Cataract Drop Candidate to Advance After New Analysis of Study Results

A new analysis of 2008 clinical study data has given a boost to Livionex’ topical drop candidate for cataracts, the John Moran Eye Center reported Aug. 16. The drop, called C-KAD, is a formulation ...

Oculis Shuts Down Phase III Trial of OCS-01 Due to Third-Party Administrative Error

Swiss company Oculis reported Aug. 27 in its Q2-2024 financial statement that it was shutting down the Phase III OPTIMIZE-2 trial of its OCS-01 eye drop candidate for postsurgical inflammation and ...

Rayner to Roll Out First Spiral IOL at 2024 ESCRS Congress

UK-based Rayner reported Aug. 26 that it was set to launch the first spiral intraocular lens models—the RayOne Galaxy and Galaxy Toric—at the 2024 ESCRS Congress, set for Sept. 6-10 in Barcelona, S...

Alcon Reports Q2-2024 Net Sales of $2.5 Billion

Alcon reported Aug. 20 that its Q2-2024 net sales totaled $2.5 billion, a record quarter for the company and a 3 percent increase (+6 percent cc) over $2.4 billion in Q2-2023. Surgical net sales fo...

Precision Lens and Estate of Paul Ehlen to Pay US $12M over Kickbacks

Minnesota-based ophthalmic distributor Precision Lens and the estate of co-founder Paul Ehlen have agreed to pay the US government $12 million to resolve a case involving kickback payments in vario...

Livionex’ Cataract Drop Candidate to Advance After New Analysis of Study Results

A new analysis of 2008 clinical study data has given a boost to Livionex’ topical drop candidate for cataracts, the John Moran Eye Center reported Aug. 16. The drop, called C-KAD, is a formulation ...

Steady Growth Expected in Single-Use Surgical Products, Even With Push to Cut OR Waste

Environmental sustainability programs have grown in scope over the last five years, with major ophthalmic surgery associations joining forces to propose specific actions to reduce the carbon footpr...

Private Equity Ownership of Surgery Centers Continues to Gain Share, Survey Shows

Private equity (PE) investment in ophthalmic practices continues to expand, even as debates over the pros and cons of these investments increase, too. For some practices that were hit hard by COVID...

Lensar Ends Collaboration with Oertli for Phaco Portion of Ally Cataract System

Lensar has terminated its collaboration agreement with Swiss company Oertli, according to a filing Aug. 5 with the US Securities and Exchange Commission. The two had been developing the Ally Adapti...

Select US FDA Approvals and Clearances in July 2024

The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in July 2024, according to the agency’s database. Topcon gained clearance for its Maestro2 OCT in c...

Meet with Market Scope at the 2024 ESCRS Congress

Market Scope will be exhibiting at the 2024 ESCRS congress, which is Sept. 6-10 in Barcelona, Spain. We will be located at Stand 6.D12. Contact us to set up a time to discuss any custom research ne...

Renowned Charity HCP Cureblindness Rebrands as Cure Blindness Project

HCP Cureblindness has rebranded as the Cure Blindness Project, the group announced July 29. The move is designed to better reflect the eye charity’s expanded geographical footprint and commitment t...

Q2-2024 Ophthalmic Revenue Roundup for AbbVie, Carl Zeiss Meditec, Amgen, STAAR, Astellas, Immunocore, Tarsus, Biogen, Lensar, and Iridex

AbbVie, of North Chicago, Illinois, reported July 25 that Q2-2024 net revenue for its eye care products totaled $533 million, a 13.3 percent decline (-10.9 percent cc) from $617 million in Q2-2023....

Lensar Ends Collaboration with Oertli for Phaco Portion of Ally Cataract System

Lensar has terminated its collaboration agreement with Swiss company Oertli, according to a filing Aug. 5 with the US Securities and Exchange Commission. The two had been developing the Ally Adapti...

Q2-2024 Ophthalmic Revenue Roundup for Hoya, Harrow, RxSight, Sight Sciences, Ocular Therapeutix, and EyePoint

Japan-based Hoya Corporation announced Aug. 1 that its medical care segment (IOLs, endoscopes, artificial bone) had revenue for the quarter ending June 30, 2024—the first quarter of its fiscal year...

Formosa Licenses Clobetasol Propionate Drops to Apotex for Canada

Taiwan-based Formosa Pharmaceuticals announced Aug. 5 that it had agreed to license to Apotex exclusive rights to market clobetasol propionate 0.05% eye drops for postsurgical inflammation and pain...

HCP Cureblindness Rebrands as Cure Blindness Project

HCP Cureblindness has rebranded as the Cure Blindness Project, the group announced July 29. The move is designed to better reflect the eye charity’s expanded geographical footprint and commitment t...

Select US FDA Approvals and Clearances in June 2024

The US FDA granted four clearances through the ophthalmic device division using the 510(k) pathway in June 2024, according to the agency’s database. Alcon gained clearance for its much-anticipated ...

Medicare Advantage Insurers Make Millions Off Ophthalmic Diagnoses They Add to Patient Records, WSJ Reports

Private insurers involved in the US Medicare Advantage program added hundreds of thousands of questionable diagnoses, including those for diabetic cataracts, to patient records in recent years to b...

MST Offers Diamond Knife Subscription Service in Move to Curb Waste

MicroSurgical Technology (MST) has launched a diamond knife subscription service for US ophthalmologists. The Redmond, Washington, company kicked off the service in April at the 2024 meeting of the...

Weekly Surgeon Poll, July 2024

Medicare Advantage Insurers Make Millions Off Ophthalmic Diagnoses They Add to Patient Records, WSJ Reports

Private insurers involved in the US Medicare Advantage program added hundreds of thousands of questionable diagnoses, including those for diabetic cataracts, to patient records in recent years to b...

J&J Vision Generates Q2-2024 Surgical Revenue of $367 Million

J&J Vision’s Q2-2024 global surgical revenue totaled $367 million, a 0.5 percent decrease (1.2 percent increase in constant currency) from $369 million in Q2-2023, parent Johnson & Johnson, of New ...

Ophthalmology Chain Clínica Baviera Enters UK Market with Acquisition of Optimax

European ophthalmology chain Clínica Baviera has extended its reach into the UK with the purchase of Optimax. Optimax (Eye Hospitals Group and subsidiaries) operates 19 clinics under the Optimax an...

Alcon Gains US FDA 510(k) Clearance for Unity VCS and CS Systems

Alcon reported June 24 that itsUnity Vitreoretinal Cataract System (VCS) and Unity Cataract System (CS) had received US FDA 510(k) clearance. The company said it would be seeking real-world feedbac...

Innovations on Horizon are Expected to Rejuvenate Cataract Equipment Market

Signs of innovation and renewal can be found in all segments of the cataract equipment market, despite evidence that the market has become mature. Innovation looms in next-generation ultrasonic pha...

Clinical Trial Updates for Ophthalmic Candidates, June 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

Surgeons, Societies Respond to MACs’ New Proposed MIGS Limits

Surgeons and ophthalmic societies worked together at open meetings in June to address five Medicare administrative contractors’ latest proposal to limit coverage of minimally invasive glaucoma surg...

June 2024 Ophthalmic News Briefs

Japan’s Nidek announced June 3 that it had launched the RS-1 Glauvas OCT system. The device is CE marked as a Class IIa device. Nidek said the RS-1 Glauvas’ streamlined workflow and advanced analyt...

MST Offers Diamond Knife Subscription Service in Move to Curb Waste

MicroSurgical Technology (MST) has launched a diamond knife subscription service for US ophthalmologists. The Redmond, Washington, company kicked off the service in April at the 2024 meeting of the...

Co-founder of HCP Cureblindness to Step Down as Board Chair, Remain Active with Charity

HCP Cureblindness, formerly known as the Himalayan Cataract Project, reported June 11 that co-founder Geoff Tabin, MD, will step down as board chair but maintain an active role with the charity as ...

WPS MAC Revisits Changing Coverage for Cataract Surgery

WPS Insurance Corporation, a Medicare administrative contractor (MAC) in the US, has again proposed changing its coverage of cataract surgery after putting forth a similar proposal in September 202...

Nidek Gains CE Marking for Preloaded IOL Injector System

Japan’s Nidek announced June 10 that it had received CE marking for the NP-1/NP-1C preloaded IOL injection system. The system is preloaded with the Aktis aspheric hydrophobic soft acrylic lens, whi...

Q1-2024 Ophthalmic Revenue Roundup for Amgen, Hoya, and Immunocore

Amgen, of Thousand Oaks, California, reported May 2 that its Q1-2024 revenue from Tepezza was $424 million. The total consisted of $419 million in the US and $5 million outside the US. The company ...

Bausch + Lomb Receives Health Canada Approval for EnVista Envy Trifocal IOL

Bausch + Lomb announced May 28 that Health Canada had approved the enVista Envy trifocal intraocular lens (IOL). It’s the first approval for the new lens. The Envy is expected to be available in Ca...

Champalimaud Vision Award Recognizes Eye Hospital Serving Gaza and West Bank

A sparsely attended Champalimaud Vision Award Lecture at the 2024 ARVO meeting highlighted the work of St. John of Jerusalem Eye Hospital in Gaza, Jerusalem, and the West Bank. Leonor Beleza, presi...

2024 ARVO Meeting Sets Attendance Record, Showcases Novel Treatment Approaches

The 2024 meeting of the Association for Research in Vision and Ophthalmology set a record as the largest ARVO meeting ever. The 11,631 registered attendees passed the old record of 10,224 set in Va...

Seattle and Phoenix Among top US Metros for Potential Growth in Premium IOL Surgery

US cataract procedures in general are driven by the over-65 population, but the premium surgery rate is fueled by a subset of comparatively affluent and healthy adults within this population. Under...

RxSight Leads Latest Ophthalmic Fundraising with $115 Million Public Offering

RxSight led recent ophthalmic fundraising efforts with a $115 million public offering to continue commercialization of its Light Adjustable Lens portfolio. Financing announced in the past four week...

Clinical Trial Updates for Ophthalmic Candidates, May 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

May 2024 Ophthalmic News Briefs

Taiwan-based Formosa Pharmaceuticals announced May 9 that it had entered into an exclusive licensing agreement with Tabuk Pharmaceuticals to market clobetasol propionate 0.05% eye drops for post-su...

Formosa Licenses Clobetasol Propionate Drops to Tabuk Pharmaceuticals for MENA Region

Taiwan-based Formosa Pharmaceuticals announced May 9 that it had entered into an exclusive licensing agreement with Tabuk Pharmaceuticals to market clobetasol propionate 0.05% eye drops for post-su...

Q1-2024 Ophthalmic Revenue Roundup for Apellis, STAAR, RxSight, Tarsus, Sight Sciences, and Three Others

Apellis Pharmaceuticals, of Waltham, Massachusetts, reported May 7 that its Q1-2024 US net product revenue for Syfovre was $137.5 million, compared with $18.4 million in Q1-2023. Syfovre gained US ...

Q1-2024 Ophthalmic Revenue Roundup for Bausch + Lomb, Glaukos, and Lumibird

Bausch + Lomb reported May 1 that its Q1-2024 revenue was $1.1 billion, an 18 percent increase (+20 percent cc) over $931 million in Q1-2023. Vision Care segment revenue in Q1-2024 was $635 million...

New Products Set Upbeat Tone for ASCRS Meeting; Attendance Remains a Concern

New product launches created high surgeon interest at the 2024 meeting of the American Society of Cataract and Refractive Surgery (ASCRS), but the overall mood of the conference was tempered somewh...

Researchers in Georgia Establish Database of Proteins in Aqueous Humor to Advance Vision Research

The National Eye Institute (NEI) announced April 8 that researchers from the Medical College of Georgia at Augusta University had established a database of the proteins found in the eye’s aqueous h...

Outlook Leads Latest Ophthalmic Fundraising with $164M in Private Placements

Retinal drug developer Outlook Therapeutics led recent ophthalmic fundraising efforts with two private placements, for proceeds totaling $164 million. Financing announced in the past four weeks tot...

ASCRS Marks 50 Years with Look Back at Cataract Surgery in 1974

The ASCRS commemorated its 50th anniversary at its 2024 annual meeting by re-creating an ophthalmologist’s office and surgery suite from the 1970s in the exhibit hall. The display served as a remin...

J&J Vision Launches Tecnis Odyssey PC-IOL at 2024 ASCRS Meeting

Johnson & Johnson Vision launched and touted the Tecnis Odyssey presbyopia-correcting IOL at a number of venues at the 2024 ASCRS meeting. Blake Williamson, MD, and Priya Matthews, MD, described J&...

RxSight Launches the LAL+ IOL with Large ASCRS Program

RxSight continued to build momentum for its post-op adjustable IOL with a big presence at the 2024 ASCRS meeting, including an Eyecelerator presentation on the new LAL+ and 14 speaker sessions at t...

Rayner and Carl Zeiss Meditec Display Recently Acquired Phaco Machines

The US ultrasonic cataract machine market has been dominated by Alcon, Bausch + Lomb, and Johnson & Johnson for more than a decade, so it’s unusual to learn of a new phaco machine being launched by...

Dry Eye Screening Before Surgery Seems Logical, but Hurdles Remain

The need to continue lobbying for dry eye evaluation prior to patients undergoing anterior segment surgery is somewhat baffling. Such testing seems like an obvious approach for the many patients wh...

BVI Medical Launches Podeye Hydrophobic Monofocal IOL in Japan

BVI Medical announced April 17 that it had launched its Podeye hydrophobic monofocal IOL in Japan, following approval by the Japanese Pharmaceuticals and Medical Devices Agency. The lens was set to...

Eyenovia Explores Strategic Alternatives as it Rolls Out Mydcombi, Postsurgical Steroid

Eyenovia reported April 8 that it is exploring strategic alternatives to maximize shareholder value, even as it rolls out Mydcombi for pupil dilation and prepares to launch its clobetasol propionat...

Weekly Surgeon Poll, April 2024

BVI Medical Launches Podeye Hydrophobic Monofocal IOL in Japan

BVI Medical announced April 17 that it had launched its Podeye hydrophobic monofocal IOL in Japan, following approval by the Japanese Pharmaceuticals and Medical Devices Agency. The lens was set to...

J&J Vision Reports Q1-2024 Surgical Revenue of $348 Million

J&J Vision’s Q1-2024 global surgical revenue totaled $348 million, up 0.3 percent (+1.1 percent cc) over $347 million in Q1-2023, parent Johnson & Johnson, of New Brunswick, New Jersey, reported Ap...

Japanese IOL Maker Hoya Halts Production After Cyberattack

Japanese intraocular lens maker Hoya reported on April 4 that production of several of its products had stopped after a computer system failure, “most likely caused by unauthorized access” to its s...

Eyenovia Explores Strategic Alternatives as it Rolls Out Mydcombi, Postsurgical Steroid

Eyenovia reported April 8 that it is exploring strategic alternatives to maximize shareholder value, even as it rolls out Mydcombi for pupil dilation and prepares to launch its clobetasol propionat...

Rayner Marks Sale of 5 Millionth RayOne IOL

UK-based Rayner reported April 3 that it had sold its 5 millionth RayOne lens and 11 millionth lens made from RayAcryl, Rayner’s proprietary hydrophilic acrylic material. Rayner, founded in 1910, r...